Iterative Therapeutics, Inc.

Chicago, IL 60612

SBIR Award Summary

Total Number of Awards 6
Total Value of Awards $1.34MM
First Award Date 06/15/04
Most Recent Award Date 09/13/17

Key Personnel

Last Name Name Awards Contact
White David M White 4
Jensen Mark Allen Jensen 2

6 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-16-302
Budget: 09/13/17 - 03/12/18

Abstract Antibody-dependent cellular cytotoxicity (ADCC) mediated by natural killer (NK) cells is a key effector function of therapeutic monoclonal antibodies (mAb) in use for treatment of established cancers. mAbs communicate with NK cells via the low-affinity Fc? receptor IIIa (Fc?RIIIa). mAbs, bound to targets on cancer cells, promote crossl...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 07/01/12 - 06/30/13

DESCRIPTION (provided by applicant): Botulinum neurotoxins (BoNTs) are the most potent protein toxins known. Given their potent toxicity and their potential use in bio-warfare scenarios, BoNTs are included among the Category A select agents. The currently available pentavalent toxoid vaccine requires multiple boosters before being effective, and...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 07/22/11 - 06/30/12

DESCRIPTION (provided by applicant): Botulinum neurotoxins (BoNTs) are the most potent protein toxins known. Given their potent toxicity and their potential use in bio-warfare scenarios, BoNTs are included among the Category A select agents. The currently available pentavalent toxoid vaccine requires multiple boosters before being effective, and...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-115
Budget: 05/01/11 - 04/30/13

DESCRIPTION (provided by applicant): Treatment of solid tumors with immunotherapy has met with limited success. One approach to tumor therapy has been to target tumors with anti-cancer monoclonal antibodies (mAbs). One of the first mAbs approved by the FDA for treatment of solid tumors is Trastuzumab which targets the HER2 receptor and is used ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-115
Budget: 05/01/10 - 04/30/11

DESCRIPTION (provided by applicant): Treatment of solid tumors with immunotherapy has met with limited success. One approach to tumor therapy has been to target tumors with anti-cancer monoclonal antibodies (mAbs). One of the first mAbs approved by the FDA for treatment of solid tumors is Trastuzumab which targets the HER2 receptor and is used ...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 06/15/04 - 05/31/07

DESCRIPTION (provided by applicant): There is currently a great need for new and more effective vaccines. Vaccines based on recombinant proteins, purified subunits, or peptides often elicit poor immune responses resulting in a failure to achieve vaccination. Our solution is to develop more effective vaccines that target antigens to antigen pres...